| 1.09 -0.15 (-12.1%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.61  |
1-year : | 1.83 |
| Resists | First : | 1.37 |
Second : | 1.57 |
| Pivot price | 1.37 |
|||
| Supports | First : | 1.07 |
Second : | 0.89 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.38 |
| MA(100) : | 1.58 |
MA(250) : | 1.04  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.8 |
D(3) : | 6.1 |
| RSI | RSI(14): 29.1 |
|||
| 52-week | High : | 3.82 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CGTX ] has closed below the lower bollinger band by 18.7%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.27 | 1.27 - 1.28 |
| Low: | 1.05 - 1.06 | 1.06 - 1.07 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Tue, 27 Jan 2026
Cognition Therapeutics Completes FDA Meeting for Zervimesine in DLB - TradingView
Tue, 27 Jan 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Tue, 06 Jan 2026
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
Tue, 06 Jan 2026
Experimental Lewy body dementia drug eases symptoms in small trial - Stock Titan
Fri, 05 Dec 2025
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance
Mon, 01 Dec 2025
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 24.3 (%) |
| Shares Short | 5,790 (K) |
| Shares Short P.Month | 6,400 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79 % |
| Return on Equity (ttm) | -109.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -2.32 |
| PEG Ratio | 0 |
| Price to Book value | 2.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|